Advances in Materials Science and Engineering

Advances in Materials Science and Engineering / 2019 / Article
Special Issue

Synthesis and Application of Novel Hybrid Nanomaterials in Catalysis, Adsorption, and Electrochemistry

View this Special Issue

Research Article | Open Access

Volume 2019 |Article ID 3534807 |

Thi Thao Do, Thi Phuong Do, Thi Nga Nguyen, Thi Cuc Nguyen, Thi Thu Phuong Vu, Thi Giang An Nguyen, "Nanoliposomal L-Asparaginase and Its Antitumor Activities in Lewis Lung Carcinoma Tumor-Induced BALB/c Mice", Advances in Materials Science and Engineering, vol. 2019, Article ID 3534807, 8 pages, 2019.

Nanoliposomal L-Asparaginase and Its Antitumor Activities in Lewis Lung Carcinoma Tumor-Induced BALB/c Mice

Guest Editor: Dinh Quang Khieu
Received14 Jan 2019
Revised15 Mar 2019
Accepted18 Mar 2019
Published02 May 2019


Although L-Asparaginase (L-ASP) is an effective chemotherapeutic agent, it has side effects such as fever, skin rashes, chills, anaphylaxis, and severe allergic reactions. Moreover, the short half-life of L-ASP reduces its antitumor activity. To reduce its side effects and broaden its pharmaceutical applications, L-ASP obtained from Pectobacterium carotovorum was subjected to liposomal conjugation. The enzyme was then loaded into liposomes using the hydrated thin-film method. The in vitro cytotoxic activity of liposomal L-ASP was evaluated with the MTT assay using cancerous cell lines, and its antitumor effects were examined in Lewis lung carcinoma (LLC) tumorized mice. The average size of the liposomes containing purified L-asparagine was 93.03 ± 0.49 nm. They had a zeta potential of –15.45 ± 6.72 mV, polydispersity index of 0.22 ± 0.02, and encapsulation efficiency of 53.99 ± 5.44%. The in vitro cytotoxic activity of liposomal L-ASP was less effective against LLC, MCF-7 (human breast carcinoma), HepG2 (human hepatocellular carcinoma), SK-LU-1 (human lung carcinoma), and NTERA-2 (pluripotent human embryonic carcinoma) cells than that of free L-ASP. However, the antitumor activity of liposomal L-ASP was significantly greater than that of untrapped L-ASP at the same doses (6 UI/mouse) in terms of tumor size (6309.11 ± 414.06 mm3) and life span (35.00 ± 1.12 days). This is the first time the antitumor activities of PEGylated nanoliposomal L-ASP have been assessed in LLC carcinoma tumor-induced BALB/c mice and showed significantly improved pharmacological properties compared to those of free L-ASP (). Thus, nanoliposomal L-ASP should be considered for its widening applications against carcinoma tumors.

1. Introduction

L-Asparaginase (L-ASP) hydrolyzes L-asparagine into L-aspartate and ammonia and is used to treat acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma [1]. Although the enzyme has been a mainstay in the treatment of ALL [24], it can induce fever, skin rashes, chills, anaphylaxis, and severe allergic reactions [5, 6]. Continued treatment leads to frequent hypersensitivity reactions in the enzyme as a foreign protein [7, 8]. To minimize the incidence of systemic immunological reactions and other limitations of L-ASP, liposomal encapsulation of the enzyme using different techniques has been adopted. The main components of liposomes are phospholipids, which are similar to cell membranes [9]. The phospholipids form a bilayer membrane, which allows drugs with different physicochemical properties to be loaded into the liposome or conjugated into the biolayers and then delivered to a lesion [10]. When liposomes are loaded with enzymes, they can be targeted to organs such as the spleen, liver, and bone marrow [11], prolonging the circulation time without inhibiting enzymatic activities [12]. L-ASP was clarified for its antitumor activities in breast tumor bearing mice by Shiromizu et al. [13]. However, liposomal L-ASP has been only reported for its improvement in vivo anticancer activities in lymphomatic mice [11]. Therefore, we developed PEGylated nanoliposomal L-ASP and first time evaluated its antitumor efficacy in Lewis lung carcinoma (LLC) tumorized BALB/c mice for broadening its pharmaceutical applications.

2. Materials and Methods

2.1. Materials

The bacterial strain Pectobacterium carotovorum was provided by Prof. Gilles Truan (Axe Biocatalyse/Ingénieries Métabolique et Moléculaire, LISBP, INSA, Toulouse, France). The strain was used for the production of L-ASP enzyme. 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG-2000) was purchased from Avanti polar lipids Inc. (Alabaster, Alabama, USA). Cholesterol, soybean lecithin, fetal bovine serum (FBS), and gentamicin was obtained from Sigma Chemical Co. (St. Louis, MO., USA). Dulbecco’s modified Eagle’s medium and nonessential amino acid (NAA) and L-glutamine was purchased from Invitrogen (Carlsbad, CA, USA).

2.2. Animals

Male and female albino BALB/c mice (8–10 weeks old) were obtained from the Institute of Biotechnology, Vietnam Academy of Science and Technology (VAST, Hanoi, Vietnam). All mice were housed in a temperature-controlled room on a 12-hour light/12-hour dark cycle with food and water ad libitum. Experiments were performed in accordance with Vietnamese Ethical Laws and European Communities Council Directives of November 24, 1986 (86/609/EEC) guidelines for the care and use of laboratory animals.

2.3. Isolation, Extraction, and Purification of L-Asparaginase

The bacterium was cultivated in the optimal medium to produce L-asparaginase as reported by Gulati et al. [14]. In details, the inoculum was prepared by adding a loop full of 250 ml cultivated medium in a 1 L flask and incubated at 30°C, 180 rpm in a shaking incubator for 12 h (to reach the culture OD at 600 nm = 0.6 to 0.8). The continued 2% of the inoculum was continuously incubated in a shaking incubator at 30°C, 180 rpm for additional 24 h. Cells were harvested by centrifugation at 10,000 g for 10 min at 4°C. Cells were washed with 50 mM Tris-HCl buffer (pH 8, 6) and resuspended in the same buffer. The cells were cooled on ice and ultrasonicated at 20 MHz, 35% amplitude, 20 min. The lysate was centrifuged at 20,000 g for 10 min at 4°C. The clear supernatant was loaded on DEAE cellulose and Sephadex G-100 chromatography for purification. The obtained eluted fractions were protein-quantitated using Pierce BCA Protein Assay Kit (Thermo Scientific) and qualified using SDS-PAGE [15].

2.4. Determination of L-Asparaginase Activity

L-ASP activity was measured by the modified method of Wriston [16] in which the rate of ammonia formation will be detected by Nessler’ reagent at 37°C. One unit of L-ASP activity was defined that liberates the amount of enzyme that released 1 µM of ammonia (with 10 µM–10 mM ammonium sulfate as the standard) per minute under the assay conditions.

2.5. Procedure for the Preparation of L-ASP Nanoliposomes

L-ASP was entrapped into liposomes by thin film dehydration-rehydration method, as Cruz et al. [17] with slight modification. Briefly, soybean lecithin (40 µmol), cholesterol (4 µmol), and DSPE-PEG-2000 (8 µmol) were dissolved in chloroform : methanol (9 : 1 v/v) and stirred mechanically to form homogeneous mixture in round bottom flask. The solvent was removed using a rotary evaporator under an aspirate vacuum (25 mmHg) and a water bath with the temperature maintained at 25°C. The thin film which formed on the walls of the flask was dispersed in 2 ml of 5 mM potassium phosphate buffer (pH 7.5) containing L-ASP (150 I.U.) and rotated without vacuum at 100 rpm, 25°C. Then, the multilamellar vesicles were sonicated three times at 30 seconds intervals for resizing before filtered through 0.22 µm membrane to receive the L-ASP liposomal mixture. Finally, the liposomal mixture was washed twice with normal saline.

The particle size, zeta potentials, and size distribution of liposomes were determined using a Zetasizer Nano-Z (Malvern Instruments, UK). The conjugates were also observed by high-solution transmission electronic microscopy (TEM) (Jeol 1200EX TEM, Jeol Company, Tokyo, Japan). The liposomal samples were mounted on metal stands and coated with gold to thickness of 200–500 A°. Then, the plates were magnified 200x to capture the morphology of the prepared liposomes.

2.6. Determination of Encapsulation Efficiency (EE)

After preparation, liposomal solution was loaded to Vivaspin column and centrifuged at 3000 RCF for 20 min, 25°C to remove the free L-ASP. The liposome pellet was lysed with 10% Triton X-100 to disrupt the liposomal bilayer and to release L-ASP. The Bradford assay was used to determine the amount of released L-ASP. Encapsulation efficiency of L-ASP into liposomes is determined as the following formula [18]:where is the encapsulated amount of L-ASP into liposomes measured after lysing with 10% Triton-X 100 and is the L-ASP amount added to the lipid mixture.

2.7. Antiproliferative Activities of L-ASP Encapsulated Nanoliposomes

The antiproliferative assays were carried out in triplicate in 96-well microtiter plates against LLC (Lewis lung carcinoma), MCF-7 (human breast carcinoma), HepG2 (human hepatocellular carcinoma), SK-LU-1 (human lung carcinoma), and NTERA-2 (pluripotent human embryonic carcinoma) cells. Those cells were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO), 1% antibiotic-antimycotic (Thermo Fisher), 1% nonessential amino acid, and 2 mM of L-glutamine. For MCF-7, insulin was added to the growth medium at 10 µg/ml concentration. All cells were incubated in a humidifier with 5% CO2 at 37°C and subcultured every 2-3 days. The cancer cells were seeded into a 96-well plate at a density of 1 × 104 cells/well. Then nanoliposomal conjugates were added to reach the final concentration ranging from 0.01–2.5 UI/mL and incubated for further 72 h. To assess effect of liposomes on cell viability, the MTT assay was performed as previously described [19].

2.8. Antitumor Efficiency of L-ASP Encapsulated Liposomes

The experiment was carried out using BALB/c mice at 20–25 gr weight. Mice were inoculated by subcutaneously injection with 1 × 106 LLC cells to induce tumor. On the day 7th of LLC cell injection, mice were randomly divided into 4 groups (6 mice per group) including a control group, two treated groups of liposomal L-ASP (6 UI/mouse and 3 UI/mouse), and the free L-ASP treated group (6 UI/mouse). The drugs were administrated intravenously every 2 days. Growth of tumor was determined by caliper measurements in two dimensions, length (L) and width (W), every 7 days. The tumor volume (V) was calculated using the formula V = 1/2 × L × W2 [20].

The survival time of mice in all experimental groups were recorded. It was calculated from the day of LLC cell inoculation to the day of death, and percentage increase in average life span (ILS) was calculated by the formula % ILS = (A/B − 1) × 100 in which A means survival time of treated, B is mean survival time of control group, and ILS is increase in average life span group.

2.9. Statistical Analysis

Statistical analyses and significance, as measured by two-way analysis of variance (ANOVA), were performed using GraphPad PRISM 5.0 software (GraphPad Software, USA). In all comparisons, was considered statistically significance.

3. Results and Discussion

3.1. Isolation, Purification, and Determination of L-ASP Activity

First, L-ASP crude extract was purified in three steps with a final yield of 23.5% and a purification fold of 9.38 (Table 1). The estimated molecular weight of the obtained enzyme was 36 kDa (Figure 1). This purified enzyme was used for further liposomal conjugation.

StepsTotal activity (IU)Total protein (mg)Specific activity (IU/mg)Purification foldYield (%)

Crude extract5972276.521.60100
Ammonium sulfate precipitation220465.433.71.5636.9
Sephadex G-100 chromatography14036.9202.69.3823.5

3.2. Physicochemical Characteristics of Liposomal L-ASP

Generally, the components of a bilayer have strong effects on the rigidity, fluidity, and toxicity of the phospholipid bilayer [21]. Nontoxic phospholipids are usually selected to reduce toxicity and to strengthen drug-liposomal conjugates, including natural and synthetic phospholipids such as soybean lecithin and DSPE-PEG-2000 [10]. Soybean lecithin is a natural phospholipid that is often used for large-scale industrial applications to reduce production costs [22]. DSPE-PEG-2000 is reported elsewhere as important breakthrough in the liposomal development pertaining stealth behavior [23]. Cholesterol is often used in liposomal formulation because it facilitates complex interactions with phospholipids and other lipids in cellular membranes [24]. Therefore, we used soybean lecithin, DSPE-PEG-2000, and cholesterol to make liposomal L-ASP, encapsulating the purified L-ASP using the rehydrated thin film method. The resulting liposomes were 93.03 ± 0.49 nm in size with a polydispersity index of 0.22 ± 0.02, indicating that the size distribution was quite homogeneous. The zeta potential is a measure of the magnitude of electrostatic or charge repulsion between particles, which affects liposome stability [2527]. The liposomes harboring L-ASP had a zeta potential of −15.45 ± 6.72 mV, the opposite of liposomes reported by Bahreini et al. that were made from chitosan and tripolyphosphate using ionotropic gelation [28]. The entrapment efficiency was determined as the ratio of encapsulated L-ASP to the amount used to prepare the liposomes. The encapsulation efficiency was 53.99%, demonstrating that L-ASP was effectively loaded into the liposomes (Table 2).

SamplesSize (nm)PDIZeta potential (mV)EE (%)

Blank liposome97.53 ± 22.170.24 ± 0.02−22.80 ± 0.00
L-ASP-liposome93.03 ± 0.490.22 ± 0.02−15.45 ± 6.7253.99 ± 5.44

Blank liposome containing soy lecithin, cholesterol, and DSPE-PEG2000.
3.3. High-Resolution Transmission Electron Microscopic Analysis

High-resolution transmission electron microscope (TEM) was used to evaluate the size, shape, and morphology of the L-ASP liposomes [26]. On TEM, the L-ASP liposomal particles were spherical and evenly dispersed (Figure 2). The obtained liposomes were nanometers in size (Figure 2).

3.4. Cytotoxicity Activities

The effects of free and liposomal L-ASP on the survival of LLC (Lewis lung carcinoma), MCF-7 (human breast carcinoma), HepG2 (human hepatocellular carcinoma), SK-LU-1 (human lung carcinoma), and NTERA-2 (pluripotent human embryonic carcinoma) cell lines were evaluated using the MTT assay. The cytotoxic activity of the liposomal L-ASP was dependent on the cancer cell line and concentrations tested (Table 3 and Figure 3). SK-LU-1 cells were the most sensitive to liposomal L-ASP and to the unloaded enzyme. The conjugates had similar activity on SK-LU-1 and LLC cells, with IC50 values of 0.21 ± 0.03 and 0.23 ± 0.02 UI/mL, respectively. MCF-7 cells were the least sensitive to both free and liposomal L-ASP. A decrease in the L-ASP concentration led to reduced cell death in all cell lines tested. Generally, malignant cells have a high division rate and need more nutrients than normal cells. Asparagine is important in cell growth and function, as it coordinates protein and nucleotide synthesis [29]. L-ASP induces cytotoxicity by breaking asparagine into L-aspartate and ammonia. According to Moharib, the cytotoxic activity of L-ASP is closely related to asparagine, and the asparagine level differed among various cell lines [30]. Therefore, L-ASP induced cancer cell death to varying degrees. However, the cytotoxic activity of the liposomal L-ASP was 3.00–5.68 times lower than that of free L-ASP after 72 h of treatment. In general, and with L-ASP, liposomal formulations are significantly less toxic than the unconjugated forms because of slow uptake. In our study, the L-ASP liposomes were less active against all cancer cells, in agreement with other studies [17]. The reduction in L-ASP cytotoxicity with liposomal encapsulation might be due to the slower release rate and slower substrate depletion, allowing cells to adapt and synthesize asparagine themselves.

SamplesValues of IC50 (UI/ml)

Loaded L-ASP liposomes0.23 ± 0.020.28 ± 0.010.21 ± 0.030.36 ± 0.050.23 ± 0.02
Free L-ASP0.079 ± 0.0010.044 ± 0.0040.037 ± 0.0010.12 ± 0.010.038 ± 0.003

3.5. In Vivo Antitumor Activity of Liposomal L-ASP

The antitumor activity of liposome-L-ASP was examined in BALB/c mice harboring tumors induced by LLC cells (Figure 4). Groups of mice were treated with two doses of liposomal L-ASP (6 or 3 UI/mouse) or free L-ASP (6 UI/mouse) intravenously. The tumor volumes of the mice were analyzed at different time points. Dose-dependent antitumor activity of liposomal L-ASP was observed. Twenty-eight days after LLC inoculation, the tumors of the group treated with 6 UI liposomal L-ASP measured 6309.11 ± 414.06 mm3, which was significantly smaller than in the negative control (9,319.35 ± 469.58 mm3, ). Liposomal L-ASP suppressed tumor growth more strongly and significantly at a dose of 6 UI than at a dose of 3 UI (7,885.80 ± 824.36 mm3) (). The tumors in the group treated with free L-ASP (7,544.94 ± 284.05 mm3) were larger than those in the group treated with liposomal L-ASP at the same dose (6 UI/mouse), and this difference was significant () (Figure 4). The mice treated with 6 UI/mouse untrapped L-ASP showed smaller volumes of tumors in comparison with the 3 UI/mouse liposomal treated group but no significance was observed (). The mean body weight of the mice in the liposomal L-ASP groups was similar to that of the negative controls at the end of the experiment, indicating that the encapsulation did not induce toxicity (data not shown).

Furthermore, the administration of liposomal L-ASP prolonged the lives of the mice (Table 4). The median survival of mice treated with 6 UI liposomal L-ASP was 35.00 ± 1.13 days, which was 12.30% longer than that of control mice (). The life span also increased slightly in the free L-ASP group, but not significantly.

GroupsMean survival time (days)% ILS

Control group (blank lipsosome)31.17 ± 1.28
Liposomal-L-ASP (3 UI/mouse)33.33 ± 0.926.95
Liposomal-L-ASP (6 UI/mouse)35.00 ± 1.1312.30
Free L-ASP (6 UI/mouse)32.17 ± 0.793.21

in comparison with the control group (blank liposome).

Since the early 1970s, L-ASP has been used to treat ALL. Currently, L-ASP is also used to treat ovarian cancer, hepatocellular carcinoma, and gastric carcinoma [31]. However, L-ASP can induce fever, thrombosis, and impaired liver, kidney, and central nervous system function, which may be related to the glutaminase activity of L-ASP [32]. According to Kumar et al. [15], L-ASP from Pectobacterium carotovorum is free of glutaminase activity, which might avoid the disadvantages of L-ASP isolated from bacteria such as Escherichia coli and Erwinia chrysanthemi. In our study, both free and liposomal L-ASP isolated from P. carotovorum showed strong activity against various solid cancer cell lines, including lung, liver, and breast carcinomas and pluripotent human embryonic carcinoma cells. Shiromizu et al. reported similar activity of L-ASP in colon cancer (C-26), a murine sarcoma cell line (S-180), and murine breast cancer (4T1) [13].

Other limitations of L-ASP treatment include its short biological half-life (T50 = 2.88 h), which necessitates increasing the dosage and intervals of L-ASP treatment [33]. Liposomes are considered an effective solution to these obstacles. Since their discovery in the 1960s, liposomes have been used as drug carriers to enhance the potency and to reduce the toxicity of therapeutic agents. Liposomes also improve the delivery of therapeutic agents to specific sites in the body [18, 34]. As reported elsewhere, solid tumors show enhanced permeability by and retention of lipids and macromolecules [35, 36]. Some effects in some solid tumors are not observed in normal tissues or organs, such as extensive angiogenesis and impaired lymphatic drainage/recovery [37]. These effects lead to higher delivery of a liposome-encapsulated drug to tumors compared with other sites. However, the size of liposomes affects the circulation of drug-loaded liposomes, especially liposomal L-ASP. Larger liposomes are easily opsonized and then rapidly removed from the blood by the mononuclear phagocytic system [38], whereas small liposomes (range 50–200 nm) increase the circulation time of loaded molecules, such as enzymes [39]. With the thin film method, simplified dehydration-rehydration vesicles produce large liposomes. However, our use of bath sonication produced liposomes smaller than 200 nm. This suitable average size helps to prolong the retention time of circulating liposomal L-ASP in vivo and its accumulation in tumors.

Additionally, the PEGylation of the liposomes helped them to avoid recognition by the mononuclear phagocytic system. Other outstanding features of PEG-coated liposomes include avoiding aggregation between liposomal particles and reduced clearance and immunogenicity [40]. These result in higher antitumor efficacy of liposomal L-ASP in vivo. However, the drug release rates of PEGylated formulations were lower than those with no PEGylation [41, 42], which may be an additional explanation for the lower in vitro cytotoxic activity of liposomal L-ASP.

4. Conclusion

Using the dehydrate-rehydrate thin film method, L-ASP was effectively encapsulated into liposome carriers at an efficiency of 53.99 ± 5.44%. PEGylated nanoliposomal L-ASP first showed significantly improved antitumor activities compared to those of free L-ASP () in LLC induced BALB/c mice but showed lower activity in an in vitro assay. Our PEGylated nanoliposomal L-ASP exhibited improved pharmacological properties and bioavailability and should be considered for further clinical applications against carcinoma tumors.

Data Availability

The physicochemical data of blank and liposomal L-ASP used to support the findings of this study are included within the supplementary information files.

Conflicts of Interest

The authors report no conflicts of interest.


The authors acknowledge the financial support from Vietnam Academy of Science and Technology [1] under the grants VAST04.10/18–19 and VAST.HTQT.PHAP.02/17-18.

Supplementary Materials

Supplementary Table 1: concentration of L-ASP in nanoliposomes. Supplementary Table 2: relative concentration of L-ASP with concentration of liposomes in Figure 3(B). Supplementary Figure 1: normalized tumor volume change to body weight after treatment with free L-ASP or liposomal L-ASP at different times. BALB/c mice harboring tumors induced by LLC cells were treated with either free L-ASP (6 UI/mouse) or encapsulated L-ASP liposomes at either 6 UI/mouse or 3 UI/mouse (n = 6). Liposome-entrapped L-ASP at both doses 6 UI/mouse and 3 UI/mouse significantly inhibited tumor growth after 28 days compared with the negative control (blank liposome) ( and , respectively). Error bars represent standard error (SE). ((Supplementary Materials))


  1. A. Shrivastava, A. A. Khan, M. Khurshid, M. A. Kalam, S. K. Jain, and P. K. Singhal, “Recent developments in L-Asparaginase discovery and its potential as anticancer agent,” Critical Reviews in Oncology/Hematology, vol. 100, pp. 1–10, 2016. View at: Publisher Site | Google Scholar
  2. M. Amylon, J. Shuster, J. Pullen et al., “Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a pediatric oncology group study,” Leukemia, vol. 13, no. 3, pp. 335–342, 1999. View at: Publisher Site | Google Scholar
  3. I. Hann, S. Richards, A. Vora et al., “Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials,” Leukemia, vol. 14, no. 3, pp. 356–363, 2000. View at: Publisher Site | Google Scholar
  4. M. Schrappe, A. Reiter, W. D. Ludwig et al., “Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group,” Blood, vol. 95, no. 11, pp. 3310–3322, 2000. View at: Google Scholar
  5. V. J. Land, W. W. Sutow, D. J. Fernbach, D. M. Lane, and T. E. Williams, “Toxicity of L-Asparaginase in children with advanced leukemia,” Cancer, vol. 30, no. 2, pp. 339–347, 1972. View at: Publisher Site | Google Scholar
  6. H. F. Oettgen, P. A. Stephenson, M. K. Schwartz et al., “Toxicity of E. coli L-Asparaginase in man,” Cancer, vol. 25, no. 2, pp. 253–278, 1970. View at: Publisher Site | Google Scholar
  7. R. W. Baldwin, “Experimental and clinical effects of L-Asparaginase,” Immunology, vol. 21, no. 4, p. 727, 1971. View at: Google Scholar
  8. R. G. Peterson, R. E. Handschumacher, and M. S. Mitchell, “Immunological responses to L-Asparaginase,” Journal of Clinical Investigation, vol. 50, no. 5, pp. 1080–1090, 1971. View at: Publisher Site | Google Scholar
  9. H. Daraee, A. Etemadi, M. Kouhi, S. Alimirzalu, and A. Akbarzadeh, “Application of liposomes in medicine and drug delivery,” Artificial Cells, Nanomedicine, and Biotechnology, vol. 44, no. 1, pp. 381–391, 2016. View at: Publisher Site | Google Scholar
  10. J. Li, X. Wang, T. Zhang et al., “A review on phospholipids and their main applications in drug delivery systems,” Asian Journal of Pharmaceutical Sciences, vol. 10, no. 2, pp. 81–98, 2015. View at: Publisher Site | Google Scholar
  11. J. O. C. S. Jorge, R. Perez-Soler, J. G. Morais, and M. E. N. M. Cruz, “Liposomal palmitoyl-L-Asparaginase: characterization and biological activity,” Cancer Chemotherapy and Pharmacology, vol. 34, no. 3, pp. 230–234, 1994. View at: Publisher Site | Google Scholar
  12. M. Jahadi and K. Khosravi-Darani, “Liposomal encapsulation enzymes: from medical applications to kinetic characteristics,” Mini-Reviews in Medicinal Chemistry, vol. 17, no. 4, pp. 366–370, 2017. View at: Publisher Site | Google Scholar
  13. S. Shiromizu, N. Kusunose, N. Matsunaga, S. Koyanagi, and S. Ohdo, “Optimizing the dosing schedule of L-Asparaginase improves its anti-tumor activity in breast tumor-bearing mice,” Journal of Pharmacological Sciences, vol. 136, no. 4, pp. 228–233, 2018. View at: Publisher Site | Google Scholar
  14. R. Gulati, R. K. Saxena, and R. Gupta, “A rapid plate assay for screening L-Asparaginase producing micro-organisms,” Letters in Applied Microbiology, vol. 24, no. 1, pp. 23–26, 1997. View at: Publisher Site | Google Scholar
  15. S. Kumar, V. Venkata Dasu, and K. Pakshirajan, “Purification and characterization of glutaminase-free L-Asparaginase from Pectobacterium carotovorum MTCC 1428,” Bioresource Technology, vol. 102, no. 2, pp. 2077–2082, 2011. View at: Publisher Site | Google Scholar
  16. J. C. Wriston Jr., “[79] asparaginase,” Glutamate, Glutamine, Glutathione, and Related Compounds, vol. 113, pp. 608–618, 1985. View at: Publisher Site | Google Scholar
  17. M. E. M. Cruz, M. M. Gaspar, F. Lopes, J. S. Jorge, and R. Perez-Soler, “Liposomal L-Asparaginase: in vitro evaluation,” International Journal of Pharmaceutics, vol. 96, no. 1–3, pp. 67–77, 1993. View at: Publisher Site | Google Scholar
  18. P. R. Kulkarni, J. D. Yadav, and K. A. Vaidya, “Liposomes: a novel drug delivery system,” International Journal of Current Pharmaceutical Research, vol. 3, no. 2, pp. 10–18, 2011. View at: Google Scholar
  19. D. A. Scudiero, R. H. Shoemaker, K. D. Paull et al., “Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines,” Cancer Research, vol. 48, no. 17, pp. 4827–4833, 1988. View at: Google Scholar
  20. M. M. Jensen, J. T. Jørgensen, T. Binderup, and A. Kjaer, “Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper,” BMC Medical Imaging, vol. 8, no. 1, 2008. View at: Publisher Site | Google Scholar
  21. A. Akbarzadeh, R. Rezaei-Sadabady, S. Davaran et al., “Liposome: classification, preparation, and applications,” Nanoscale Research Letters, vol. 8, no. 1, p. 102, 2013. View at: Publisher Site | Google Scholar
  22. P. van Hoogevest and A. Wendel, “The use of natural and synthetic phospholipids as pharmaceutical excipients,” European Journal of Lipid Science and Technology, vol. 116, no. 9, pp. 1088–1107, 2014. View at: Publisher Site | Google Scholar
  23. O. Nag and V. Awasthi, “Surface engineering of liposomes for stealth behavior,” Pharmaceutics, vol. 5, no. 4, pp. 542–569, 2013. View at: Publisher Site | Google Scholar
  24. M.-L. Briuglia, C. Rotella, A. McFarlane, and D. A. Lamprou, “Influence of cholesterol on liposome stability and on in vitro drug release,” Drug Delivery and Translational Research, vol. 5, no. 3, pp. 231–242, 2015. View at: Publisher Site | Google Scholar
  25. S. Honary and F. Zahir, “Effect of zeta potential on the properties of nano-drug delivery systems-a review (part 2),” Tropical Journal of Pharmaceutical Research, vol. 12, no. 2, pp. 265–273, 2013. View at: Publisher Site | Google Scholar
  26. S. Salgin, U. Salgin, and S. Bahadir, “Zeta potentials and isoelectric points of biomolecules: the effects of ion types and ionic strengths,” International Journal of Electrochemical Science, vol. 7, no. 12, pp. 12404–12414, 2012. View at: Google Scholar
  27. Y. Zhang, M. Yang, N. G. Portney et al., “Zeta potential: a surface electrical characteristic to probe the interaction of nanoparticles with normal and cancer human breast epithelial cells,” Biomedical Microdevices, vol. 10, no. 2, pp. 321–328, 2008. View at: Publisher Site | Google Scholar
  28. E. Bahreini, K. Aghaiypour, R. Abbasalipourkabir, A. Mokarram, M. Goodarzi, and M. Saidijam, “Preparation and nanoencapsulation of L-Asparaginase II in chitosan-tripolyphosphate nanoparticles and in vitro release study,” Nanoscale Research Letters, vol. 9, no. 1, p. 340, 2014. View at: Publisher Site | Google Scholar
  29. A. S. Krall, S. Xu, T. G. Graeber, D. Braas, and H. R. Christofk, “Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor,” Nature Communications, vol. 7, no. 1, p. 11457, 2016. View at: Publisher Site | Google Scholar
  30. S. A. Moharib, “Anticancer activity of L-Asparaginase produced from vigna unguiculata,” World Scientific Research, vol. 5, no. 1, pp. 1–12, 2018. View at: Publisher Site | Google Scholar
  31. D. Covini, S. Tardito, O. Bussolati et al., “Expanding targets for a metabolic therapy of cancer: L-Asparaginase,” Recent Patents on Anti-Cancer Drug Discovery, vol. 7, no. 1, pp. 4–13, 2012. View at: Publisher Site | Google Scholar
  32. L. Huang, Y. Liu, Y. Sun, Q. Yan, and Z. Jiang, “Biochemical characterization of a novel L-Asparaginase with low glutaminase activity from Rhizomucor miehei and its application in food safety and leukemia treatment,” Applied and Environmental Microbiology, vol. 80, no. 5, pp. 1561–1569, 2014. View at: Publisher Site | Google Scholar
  33. A. De and D. N. Venkatesh, “Design and evaluation of liposomal delivery system for L-Asparaginese,” Journal of Applied Pharmaceutical Science, vol. 2, no. 8, p. 112, 2012. View at: Google Scholar
  34. A. Babu, A. K. Templeton, A. Munshi, and R. Ramesh, “Nanodrug delivery systems: a promising technology for detection, diagnosis, and treatment of cancer,” AAPS PharmSciTech, vol. 15, no. 3, pp. 709–721, 2014. View at: Publisher Site | Google Scholar
  35. H. Kobayashi, R. Watanabe, and P. L. Choyke, “Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target,” Theranostics, vol. 4, no. 1, pp. 81–89, 2013. View at: Publisher Site | Google Scholar
  36. A. D. Wong, M. Ye, M. B. Ulmschneider, and P. C. Searson, “Quantitative analysis of the enhanced permeation and retention (EPR) effect,” PloS One, vol. 10, no. 5, Article ID e0123461, 2015. View at: Publisher Site | Google Scholar
  37. S. Stapleton, M. Milosevic, C. Allen et al., “A mathematical model of the enhanced permeability and retention effect for liposome transport in solid tumors,” PloS One, vol. 8, no. 12, Article ID e81157, 2013. View at: Publisher Site | Google Scholar
  38. A. C. Anselmo, V. Gupta, B. J. Zern et al., “Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells,” ACS Nano, vol. 7, no. 12, pp. 11129–11137, 2013. View at: Publisher Site | Google Scholar
  39. M. M. Gaspar, R. Perez-Soler, and M. E. M. Cruz, “Biological characterization of L-Asparaginase liposomal formulations,” Cancer Chemotherapy and Pharmacology, vol. 38, no. 4, pp. 373–377, 1996. View at: Publisher Site | Google Scholar
  40. M. L. Immordino, F. Dosio, and L. Cattel, “Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential,” International Journal of Nanomedicine, vol. 1, no. 3, pp. 297–315, 2006. View at: Google Scholar
  41. F. Atyabi, A. Farkhondehfai, F. Esmaeili, and R. Dinarvand, “Preparation of pegylated nano-liposomal formulation containing SN-38: in vitro characterization and in vivo biodistribution in mice,” Acta Pharmaceutica, vol. 59, no. 2, pp. 133–144, 2009. View at: Publisher Site | Google Scholar
  42. L. Cai, X. Wang, W. Wang et al., “Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo,” International Journal of Nanomedicine, vol. 7, pp. 4499–4510, 2012. View at: Publisher Site | Google Scholar

Copyright © 2019 Thi Thao Do et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles